Florida is currently home to 3768 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
In-Utero Endoscopic Correction of Spina Bifida
Recruiting
The purpose of this study is to evaluate the feasibility and effectiveness of performing fetoscopic surgical correction of fetal spina bifida. Two surgical approaches will be utilized: the percutaneous technique versus the laparotomy/uterine exteriorization technique.
Gender:
FEMALE
Ages:
Between 18 years and 52 years
Trial Updated:
03/24/2025
Locations: Wellington Regional Medical Center, Wellington, Florida
Conditions: Neural Tube Defects, Spina Bifida, Myelomeningocele
Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®
Recruiting
Prospective data will be collected in approximately 3500 patients (700 per 5 injury groups). Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, patient reported outcomes (PROs), anticipated or procedure-related adverse events (i.e. complications), and radiological outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Miami, Jackson Memorial Hospital Ryder Trauma Center, Miami, Florida
Conditions: Hip Fractures, Tibial Fractures, Ankle Fractures, Humeral Fracture, Proximal, Distal Radius Fracture
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Naples Community Hospital, Naples, Florida
Conditions: Stroke, PFO - Patent Foramen Ovale
Short Course Radiotherapy for the Treatment of Patients with Glioblastoma, SAGA Study
Recruiting
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Glioblastoma
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: Innovative Research of West Florida, Inc., Clearwater, Florida
Conditions: Hypertriglyceridemia
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: AnaptysBio Investigational Site 10-127, Brooksville, Florida
Conditions: Ulcerative Colitis
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors or lymphoma that has spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is in a class of drugs called histone deacetylase (HDAC) inhibitor. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Advanced Pancreatic Carcinoma, B-Cell Non-Hodgkin Lymphoma, Metastatic Pancreatic Carcinoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
Recruiting
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/21/2025
Locations: American Access Care of Jacksonville, Jacksonville, Florida
Conditions: Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
Recruiting
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: AdventHealth Orlando /ID# 267970, Orlando, Florida
Conditions: Metastatic Colorectal Cancer
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Recruiting
The goal of this clinical study is to learn about the safety and tolerability of bictegravir/lenacapavir (BIC/LEN) and to learn how the study drug interacts with the body in virologically suppressed (VS) children and adolescents with human immunodeficiency virus type 1 (HIV-1) on a stable and complex antiretroviral (ARV) regimen. The study will also assess the safe loading dose of LEN and pharmacokinetics (PK) of BIC/LEN. The primary objectives of this study are: * To evaluate the steady-state... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/21/2025
Locations: University of South Florida, Tampa, Florida
Conditions: HIV-1-infection
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
Recruiting
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/21/2025
Locations: University of Miami, Miami, Florida
Conditions: Lung Diseases
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis
Recruiting
The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene.
Gender:
ALL
Ages:
Between 30 years and 55 years
Trial Updated:
03/21/2025
Locations: The University of South Florida Board of Trustees, Tampa, Florida
Conditions: Sensorineural Hearing Loss, Bilateral